Hypocretin/orexin loss changes the hypothalamic immune response.
Hypocretin, also known as orexin, maintains the vigilance state and regulates various physiological processes, such as arousal, sleep, food intake, energy expenditure, and reward. Previously, we found that when wild-type mice and hypocretin/ataxin-3 littermates (which are depleted of hypothalamic hypocretin-expressing neurons postnatally) were administered lipopolysaccharide (LPS), the two genotypes exhibited significant differences in their sleep/wake cycle, including differences in the degree of increase in sleep periods and in recovery from sickness behaviour. In the present study, we examined changes in the hypothalamic vigilance system and in the hypothalamic expression of inflammatory factors in response to LPS in hypocretin/ataxin-3 mice. Peripheral immune challenge with LPS affected the hypothalamic immune response and vigilance states. This response was altered by the loss of hypocretin. Hypocretin expression was inhibited after LPS injection in both hypocretin/ataxin-3 mice and their wild-type littermates, but expression was completely abolished only in hypocretin/ataxin-3 mice. Increases in the number of histidine decarboxylase (HDC)-positive cells and in Hdc mRNA expression were found in hypocretin/ataxin-3 mice, and this increase was suppressed by LPS. Hypocretin loss did not impact the change in expression of hypothalamic inflammatory factors in response to LPS, except for interferon gamma and colony stimulating factor 3. The number of c-Fos-positive/HDC-positive cells in hypocretin/ataxin-3 mice administered LPS injections was elevated, even during the rest period, in all areas, suggesting that there is an increase in the activity of histaminergic neurons in hypocretin/ataxin-3 mice following LPS injection. Taken together, our results suggest a novel role for hypocretin in the hypothalamic response to peripheral immune challenge. Our findings contribute to the understanding of the pathophysiology of narcolepsy.
Department of Anatomy and Cell Science, Kansai Medical University, Hirakata, Japan; SLEEP Disorders Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. Electronic address: tanakass@hirakata.kmu.ac.jp.
Susumu
S
Tanaka
Department of Anatomy and Cell Science, Kansai Medical University, Hirakata, Japan.
Nae
N
Takizawa
SLEEP Disorders Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Yoshiko
Y
Honda
Department of Anatomy and Cell Science, Kansai Medical University, Hirakata, Japan.
Taro
T
Koike
Department of Anatomy and Cell Science, Kansai Medical University, Hirakata, Japan.
Souichi
S
Oe
SLEEP Disorders Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiromi
H
Toyoda
SLEEP Disorders Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Tohru
T
Kodama
Department of Anatomy and Cell Science, Kansai Medical University, Hirakata, Japan.
Hisao
H
Yamada
D000818:Animals; D000067699:Ataxin-3 / Q000378:metabolism; D015870:Gene Expression; D007031:Hypothalamus / Q000276:immunology* / Q000378:metabolism*; D007249:Inflammation / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D000068797:Orexins / Q000378:metabolism*; D012890:Sleep / Q000276:immunology*; D014851:Wakefulness
D008070:Lipopolysaccharides; D000068797:Orexins; D000067699:Ataxin-3; C511594:Atxn3 protein, mouse
Histamine; Hypocretin/orexin; Hypothalamus; Immunity; Sleep/wake